drugs to combat

Develops new

QURETECH BIO2024-07-03T12:22:11+00:00

QureTech Bio’s vision is to develop first-in-class drugs to combat infectious diseases and the occurrence of antibiotic resistance

QureTech Bio address a significant unmet medical need by developing new antibacterial agents that targets different infectious diseases including healthcare-associated infections and tuberculosis. This is done either by a direct antimicrobial effect or by potentiating existing antibiotics. The compounds are new small molecules from a well-developed chemical platform with excellent synthetic availability and desirable drug properties. The company has established a strong IPR portfolio based on separate patent applications for each of the development programs.

The company’s lead program is focused on developing a new class of antibiotics effective against multidrug resistant Gram-positive bacteria. Read more about the GmPcide program here.

The tuberculosis project is developed in partnership with Fimbrion Therapeutics and is supported by Phase I SBIR funding from NIH/NIAID.

Latest News


We are actively seeking investors and collaboration partners to enable development and commercialization of the company’s pipeline programs.

Welcome to contact us for more information about partnership opportunities.

Fredrik Almqvist, Quretech Bio


Annica Rönnbäck, Quretech Bio


Go to Top